A quantitative bifunctional in vitro potency assay for botulinum neurotoxin serotype A.

J Pharmacol Toxicol Methods

Revance Therapeutics, 7444 Gateway Blvd., Newark, CA 94560, United States.

Published: March 2016

Introduction: Botulinum neurotoxin type A (BoNTA) is one of seven serotypes produced by Clostridium botulinum (types A thru G) and is the serotype most widely used to treat both cosmetic and medical conditions. Potency for botulinum toxin preparations is expressed in mouse LD50 units. There is a need to develop a non-animal based replacement for this potency assay.

Methods: An in vitro potency assay measuring BoNTA activity has been developed that addresses both BoNTA heavy chain binding to its cell receptor SV2C and BoNTA light chain enzymatic activity in cleaving SNAP-25, an intracellular protein essential in neurotransmitter release. This bifunctional assay utilizes a 96 well microtiter format and well defined reagents. Assay characterization determined that the relative standard deviation for intermediate precision was less than 10%.

Results: The assay standard curve covers the range of BoNTA concentrations from 0.0624 to 32 ng/mL. Specificity was demonstrated with purified BoNTA heavy chain which inhibited the activity in a dose dependent manner. A correlation between this bifunctional assay and the mouse LD50 potency assay was demonstrated.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vascn.2013.12.002DOI Listing

Publication Analysis

Top Keywords

potency assay
12
vitro potency
8
botulinum neurotoxin
8
mouse ld50
8
bonta heavy
8
heavy chain
8
bifunctional assay
8
assay
7
bonta
6
potency
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!